• Harry Erba, M.D., Ph.D., is a Professor of Medicine, Director of the UAB Hematologic Malignancy Program and Associate Director for Clinical Research at the UAB Comprehensive Cancer Center.

    Dr. Erba received his M.D. and Ph.D. degrees from Stanford University. He did his internship and residency in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School. Following a fellowship in hematology/oncology at the same institution, he joined the Harvard Medical School faculty for 3 years until he moved to the University of Michigan at Ann Arbor where he rose to the rank of Associate Professor.Over the past decade Dr. Erba has become a highly respected leader in the field of hematologic malignancies, especially with respect to the assessment of novel therapies in acute myeloid leukemia, chronic myeloid leukemia and myelodysplastic syndromes. He is an executive officer of SWOG (formerly, Southwest Oncology Group), working closely with the leadership of the SWOG leukemia, lymphoma, myeloma and bone marrow transplant committees. He is an active member in the SWOG leukemia committee and will become chair in the next month.

    He has served on the National Comprehensive Cancer Network (NCCN) Practice Guidelines Committees for acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndromes and myeloid growth factors. He was given Special Recognition and Appointment to the NCCN Board of Producers in 2007 and 2008. He has been involved in numerous clinical trials in hematologic malignancies, led many national trials as a chair or co-chair, and played major roles in the development of several new drugs. He was named Teacher of the Year in the Division of Hematology/Oncology for four consecutive years at the University of Michigan. In 2004 he was given the Outstanding Clinician Award by the Dean of the University of Michigan Medical School, and this year was appointed as an inaugural member of the League of Clinical Excellence at the University of Michigan.

    His work has been published in high-impact journals such as Nature, Cell, Journal of Clinical Oncology, Blood, Cancer Research and British Journal of Haematology. In addition to 47 peer-reviewed publications, he has authored five book chapters and has lectured extensively in the US, Canada, Europe and Japan.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Shifting paradigms in the treatment of older adults with AMLSeminars in Hematology.  56:110-117. 2019
    2019 The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)Leukemia Research.  78:29-33. 2019
    2019 Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studiesLeukemia.  33:371-378. 2019
    2019 Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trialsLeukemia.  33:554-558. 2019
    2018 Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLLNew England Journal of Medicine.  379:2517-2528. 2018
    2018 Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey *Leukemia & Lymphoma.  59:2723-2726. 2018
    2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowLeukemia Research.  74:64-67. 2018
    2018 Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasmsLeukemia.  32:2352-2362. 2018
    2018 A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AMLBlood.  132:1125-1133. 2018
    2018 Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesBlood.  131:2782-2788. 2018
    2018 Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AMLNew England Journal of Medicine.  378:2386-2398. 2018
    2018 Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML)Leukemia Research.  67:17-20. 2018
    2018 Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AMLBlood.  131:1415-1424. 2018
    2018 Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG ReportBiopreservation and Biobanking.  16:42-52. 2018
    2018 Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemiaAmerican Journal of Hematology.  93:E49-E52. 2018
    2018 A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaBlood.  131:387-396. 2018
    2017 Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American intergroup study swog s1117Journal of Clinical Oncology.  35:2745-2753. 2017
    2017 Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 studyLancet Oncology.  18:1061-1075. 2017
    2017 Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsCancer.  123:2472-2481. 2017
    2017 Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA eraBlood.  129:1763-1767. 2017
    2017 Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromesBlood Cancer Journal.  7. 2017
    2017 Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208Journal of Cancer Survivorship.  11:32-40. 2017
    2017 Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United StatesTransfusion.  57:289-295. 2017
    2016 In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemiaPLoS ONE.  11. 2016
    2016 Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemiaLeukemia.  30:2080-2083. 2016
    2016 Connect MDS/AML: Design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort studyBMC Cancer.  16. 2016
    2016 Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first courseLeukemia.  30:1779-1780. 2016
    2016 Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsLeukemia Research.  42:68-74. 2016
    2016 Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: Further results of the E1905 North American Leukemia Intergroup studyBritish Journal of Haematology.  172:384-391. 2016
    2016 Relationship between event-free survival and overall survival in acute myeloid leukemia: A report from SWOG, HOVON/SAKK, and MRC/NCRIHaematologica.  101:e284-e286. 2016
    2015 Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: Analysis of 1,892 patients from HOVON/SAKK and SWOGHaematologica.  100:e409-e411. 2015
    2015 Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 studyLancet Oncology.  16:1025-1036. 2015
    2015 In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer DrugsMayo Clinic Proceedings.  90:996-1000. 2015
    2015 Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - Results of a phase i dose-escalation studyClinical Lymphoma, Myeloma and Leukemia.  15:443-449. 2015
    2015 Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaJournal of Clinical Oncology.  33:1252-1257. 2015
    2015 Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsBlood.  125:1367-1376. 2015
    2015 Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemiaHaematologica.  100:331-335. 2015
    2015 Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction TherapyBiology of Blood and Marrow Transplantation.  21:559-564. 2015
    2015 Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapyLeukemia Research.  39:183-191. 2015
    2015 Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment-free remissionAmerican Journal of Hematology.  90:242-249. 2015
    2015 Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: A phase 1 studyBritish Journal of Haematology.  169:534-543. 2015
    2015 Recent developments in the treatment of older individuals with acute myeloid leukemia: 2014Current opinion in hematology.  22:108-115. 2015
    2014 A multicenter phase l/ll study of obatoclax mesylate administered as a 3- Or 24-hour infusion in older patients with previously untreated acute myeloid leukemiaPLoS ONE.  9. 2014
    2014 Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905Journal of Clinical Oncology.  32:1242-1248. 2014
    2014 Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Leukemia Research.  38:329-333. 2014
    2014 Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD AndersonLeukemia.  28:289-292. 2014
    2014 Phase 2 study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: A university of chicago phase 2 consortium trialClinical Cancer Research.  20:490-498. 2014
    2014 Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromesBritish Journal of Haematology.  166:352-359. 2014
    2014 Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSSBritish Journal of Haematology.  167:62-68. 2014
    2013 Expert insights into the contemporary management of older adults with acute myeloid leukemiaCancer Control : Journal of the Moffitt Cancer Center.  20:5-16. 2013
    2013 A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaBlood.  122:3432-3439. 2013
    2013 Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)Investigational New Drugs.  31:1023-1034. 2013
    2013 A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaBlood.  121:4854-4860. 2013
    2012 Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemiaLeukemia & Lymphoma.  53:435-440. 2012
    2012 Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML.Expert Review of Anticancer Therapy.  12:1289-1297. 2012
    2011 Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemiaBlood.  118:5914-5917. 2011
    2011 Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignanciesBlood.  118:4258-4264. 2011
    2011 Improving frontline treatment for chronic myeloid leukemia: Emerging evidence for use of nilotinib and dasatinibClinical Advances in Hematology and Oncology.  9:734-745. 2011
    2011 A pathobiological role of the insulin receptor in chronic lymphocytic leukemiaClinical Cancer Research.  17:2679-2692. 2011
    2011 Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood.  117:3294-3301. 2011
    2011 A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemiaCancer.  117:1253-1261. 2011
    2011 Targeting protein neddylation: A novel therapeutic strategy for the treatment of cancerExpert Opinion on Therapeutic Targets.  15:253-264. 2011
    2010 Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemiaBlood.  116:4958-4967. 2010
    2010 Has there been progress in the treatment of older patients with acute myeloid leukemia?Baillieres Clinical Haematology.  23:495-501. 2010
    2010 NF1 inactivation in adult acute myelogenous leukemiaClinical Cancer Research.  16:4135-4147. 2010
    2010 Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemiaBlood.  116:71-80. 2010
    2010 Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factorsJournal of Clinical Oncology.  28:549-555. 2010
    2010 Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaBritish Journal of Haematology.  148:48-58. 2010
    2009 NCCN Task Force report: Molecular markers in leukemias and lymphomasJournal of the National Comprehensive Cancer Network.  7. 2009
    2009 Chronic myelogenous leukemiaJournal of the National Comprehensive Cancer Network.  7:984-1023. 2009
    2009 Myeloid growth factorsJournal of the National Comprehensive Cancer Network.  7:64-83. 2009
    2008 Acute myeloid leukemiaJournal of the National Comprehensive Cancer Network.  6:962-992. 2008
    2008 Myelodysplastic syndromesJournal of the National Comprehensive Cancer Network.  6:902-925. 2008
    2008 Genomic complexity identifies patients with aggressive chronic lymphocytic leukemiaBlood.  112:1993-2003. 2008
    2008 Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14Cancer Research.  68:1012-1021. 2008
    2008 Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemiaBlood.  111:1584-1593. 2008
    2007 In Vitro and In Silico Analysis of Annexin V Binding to Lymphocytes as a Biomarker in Emergency Department Sepsis StudiesAcademic Emergency Medicine.  14:763-771. 2007
    2007 Institutional experience with voriconazole compared with liposomal amphotericin b as empiric therapy for febrile neutropeniaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  27:970-979. 2007
    2007 Chronic myelogenous leukemiaJournal of the National Comprehensive Cancer Network.  5:474-496. 2007
    2007 Myeloid growth factors: Clinical practice guidelines in oncology™Journal of the National Comprehensive Cancer Network.  5:188-202. 2007
    2007 Prognostic factors in elderly patients with AML and the implications for treatment.Hematology online (ASH).  420-428. 2007
    2006 Acute myeloid leukemia: Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network.  4:16-36. 2006
    2006 Myelodysplastic syndromes: Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network.  4:58-77. 2006
    2005 Chronic myelogenous leukemia: Clinical practice guidelines in oncologyJournal of the National Comprehensive Cancer Network.  3:732-755. 2005
    2004 Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.Current Hematology Reports.  3:47-53. 2004
    2003 Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133Journal of Clinical Oncology.  21:3512-3519. 2003
    2003 Recent progress in the treatment of myelodysplastic syndrome in adult patientsCurrent Opinion in Oncology.  15:1-9. 2003
    2002 Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)Leukemia.  16:1627-1636. 2002
    2000 NCCN Practice Guidelines for Acute Myelogenous Leukemia.Oncology.  14:53-61. 2000
    2000 NCCN Practice Guidelines for Chronic Myelogenous Leukemia.Oncology.  14:229-240. 2000
    2000 Reversible pulmonary hypertension in POEMS syndrome - Another etiology of triggered pulmonary vasculopathy?Canadian Journal of Cardiology.  16:1007-1012. 2000
    1988 Cytoskeletal actin gene families of Xenopus borealis and Xenopus laevisJournal of Molecular Evolution.  27:17-28. 1988
    1988 Modulation of microfilament protein composition by transfected cytoskeletal actin genesMolecular and Cellular Biology.  8:1790-1794. 1988
    1988 Nucleotide sequence and expression of the human skeletal α-actin gene: Evolution of functional regulatory domainsGenomics.  3:323-336. 1988
    1988 Structure, chromosome location, and expression of the human γ-actin gene: Differential evolution, location, and expression of the cytoskeletal β- and γ-actin genesMolecular and Cellular Biology.  8:1775-1789. 1988
    1986 Nucleotide sequence of the human γ cytoskeletal actin mRNA: Anomalous evolution of vertebrate non-muscle actin genesNucleic Acids Research.  14:5275-5294. 1986
    1981 Histone genes are located at the sphere loci of newt lampbrush chromosomesChromosoma.  84:159-171. 1981
    1981 Characterization of a cloned histone gene cluster of the newt notophthalmus viridescensNucleic Acids Research.  9:2281-2295. 1981
    1981 Histone gene clusters of the newt notophthalmus are separated by long tracts of satellite DNACell.  24:639-647. 1981
    1980 Satellite DNA is transcribed on lampbrush chromosomes [24]Nature.  283:686-688. 1980
    1980 Cytological evidence of transcription of highly repeated DNA sequences during the lampbrush stage in Triturus cristatus carnifexChromosoma.  80:289-307. 1980


    Year Title Altmetric
    2014 Cytogenetics and Prognostic Models in Myelodysplastic Syndromes.  106-112. 2014

    Full Name

  • Harry Erba